Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd

Equities

301126

CNE1000054V3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-05-22 EDT 5-day change 1st Jan Change
9.81 CNY -7.19% Intraday chart for Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd -3.06% -24.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 119.999994 million in funding CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Board Elections CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed the share acquisition agreement to acquire 51% stake in Shanxi Simaile Pharmaceutical Chain Co., Ltd. from Yang Jinjiang, Liu Hongming for approximately CNY 330 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd agreed to acquire Yinchuan Meihetai Pharmaceutical Chain Co., Ltd. from Xie Huiyang and Xie Xiaolong for approximately CNY 250 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Implements Final Cash Dividend of A Shares for the Year 2022, Payable on June 12, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Final Cash Dividend for 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd cancelled the transaction announced on May 18, 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 300 million in funding CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Proposes Final Cash Dividend for the Year 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Tongjian Pharmacy to Buy 86% Stake in Local Peer For 341 Million Yuan MT
Hunan Tongjian Pharma to Buy 86% of Local TCM Maker For 341 Million Yuan MT
Certain A Shares of Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. are subject to a Lock-Up Agreement Ending on 8-DEC-2022. CI
Hunan Dajiaweikang Pharma to Buy 85.7% Stake in Pharma Firm CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed a Share Transfer Agreement to acquire a 85.7143% stake in Hunan Tianjicaotang Pharmaceutical CO.,LTD. from Weng Xiaotao and Xiang Zhongyou for CNY 340 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd completed the acquisition of 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd agreed to acquire 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng for approximately CNY 140 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 21 June 2022 CI
Hunan Tongjian Pharmacy to Free Up 2.7 Million Shares For Trading MT
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. Approves Cash Dividend CI
Chart Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd
More charts
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is a China-based company mainly engaged in the distribution and retail business of drugs, biological products, medical devices and other products. The Company is also engaged in reproductive hospital business. The pharmaceutical distribution business includes pure sales mode and allocation mode, mainly engaged in anti-tumor drugs, immunomodulatory drugs, cardiovascular and cerebrovascular drugs, respiratory drugs, antiviral drugs and other new and special drugs. The pharmaceutical retail business is mainly engaged in professional pharmacies, focusing on the sales of prescription drugs, mainly including Special Service pharmacy business and direct to patient (DTP) pharmacy business. The reproductive hospital business is mainly engaged in the diagnosis and treatment of gynecological and urological diseases.
More about the company
  1. Stock Market
  2. Equities
  3. 301126 Stock
  4. News Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd
  5. Hunan Tongjian Pharma to Buy 86% of Local TCM Maker For 341 Million Yuan